BrainStorm Cell Therapeutics, Inc. (BCLI) to Receive European Patent Covering Stem Cell Technology Treatment of CNS Diseases
BrainStorm Cell Therapeutic, a biotech company engaged in the development of adult stem cell therapies for the treatment of neurodegenerative diseases, has received notification from the European Patent Office (EPO) that it intends to grant to the company its patent application No. EP06766101.7. This patent, entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases,” covers the method of production of the company's proprietary technology that induces autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. BrainStorm’s proprietary NurOwn™ stem cell therapy was developed from this…